BERLIN October 19, 2025 – Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when ...
Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing ...
GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate cancer treatment, fuelling the ongoing industry buzz for the promising ...
Add Yahoo as a preferred source to see more of our stories on Google. Merck KGaA will progress its ADC Merck KGaA's antibody-drug conjugate (ADC), precemtabart tocentecan (Precem-TcT), has shown ...
Back-to-back Presidential Symposium presentations of ENHERTU from DESTINY-Breast11 and DESTINY-Breast05 demonstrate its potential to become a foundational treatment in curative-intent settings of HER2 ...
BETHESDA, Md., Feb. 13, 2026 /PRNewswire/ -- Precision Biologics, Inc. CEO Philip M. Arlen, MD gives a Keynote presentation describing in vitro and in vivo efficacy of its novel tumor-specific ...
Enhertu, a targeted cancer therapy from partners AstraZeneca and Daiichi Sankyo, may now be used as a first-line treatment for advanced cases of breast cancer, making it the first new approved ...
Hosted on MSN
ADC improves outcomes in advanced triple-negative breast cancer patients ineligible for immune checkpoint inhibitors
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results